Show simple item record

dc.contributor.authorJones, RH
dc.contributor.authorCasbard, A
dc.contributor.authorCarucci, M
dc.contributor.authorFoxley, A
dc.contributor.authorHowell, Sacha J
dc.date.accessioned2020-06-15T12:57:38Z
dc.date.available2020-06-15T12:57:38Z
dc.date.issued2020en
dc.identifier.citationJones RH, Casbard A, Carucci M, Foxley A, Howell SJ. Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply. Lancet Oncol. 2020;21(5):e234.en
dc.identifier.pmid32359499en
dc.identifier.doi10.1016/s1470-2045(20)30237-0en
dc.identifier.urihttp://hdl.handle.net/10541/622973
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/ 10.1016/s1470-2045(20)30237-0en
dc.titleFulvestrant plus capivasertib for metastatic breast cancer - Authors' replyen
dc.typeArticleen
dc.contributor.departmentVelindre Cancer Centre, Cardiff, UK.en
dc.identifier.journalLancet Oncologyen
dc.description.noteen]
refterms.dateFOA2020-06-22T12:12:43Z


Files in this item

Thumbnail
Name:
LancOnc.pdf
Size:
34.69Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record